{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Magazine", "lead_paragraph": "The author\u2019s 9-year-old son suffered more than 100 seizures a day. When he started a high-fat, very low-carb diet, the number dropped by three-quarters.", "headline": {"seo": "Epilepsy\u2019s Big Fat Miracle", "main": "Epilepsy\u2019s Big Fat Miracle", "print_headline": "A Big, Fat Miracle"}, "abstract": null, "print_page": "50", "word_count": "4790", "_id": "5420a8347988104c4a501658", "snippet": "The author\u2019s 9-year-old son suffered more than 100 seizures a day. When he started a high-fat, very low-carb diet, the number dropped by three-quarters.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2010/11/21/magazine/21Epilepsy-t.html", "multimedia": [{"width": 600, "url": "images/2010/11/21/magazine/21epilepsy-span/21epilepsy-span-articleLarge.jpg", "height": 413, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlarge": "images/2010/11/21/magazine/21epilepsy-span/21epilepsy-span-articleLarge.jpg", "xlargeheight": "413"}, "type": "image"}, {"width": 75, "url": "images/2010/11/21/magazine/21epilepsy-span/21epilepsy-span-thumbStandard-v2.jpg", "height": 75, "subtype": "thumbnail", "legacy": {"thumbnailheight": "75", "thumbnail": "images/2010/11/21/magazine/21epilepsy-span/21epilepsy-span-thumbStandard-v2.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"rank": "1", "is_major": "N", "value": "Epilepsy", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Seizures (Medical)", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Children and Youth", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Diet and Nutrition", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Oils and Fats", "name": "subject"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "firstname": "Fred", "rank": 1, "lastname": "VOGELSTEIN"}], "original": "By FRED VOGELSTEIN"}, "document_type": "article", "pub_date": "2010-11-21T00:00:00Z", "section_name": "Magazine"}, {"type_of_material": "Blog", "blog": [], "news_desk": null, "lead_paragraph": "Patients with chronic kidney disease who took Vytorin, a cholesterol-lowering pill, had one-sixth fewer heart attacks, strokes or operations to unblock their arteries than patients taking a placebo, according to the results of a new study presented on Saturday.", "headline": {"main": "Study Suggests a Cholesterol Pill Benefits Kidney Patients", "kicker": "Prescriptions"}, "abstract": "A new study reports heart benefits for patient with chronic kidney disease who took Vytorin to lower their cholesterol.", "print_page": null, "word_count": 994, "_id": "4fd39d258eb7c8105d8de182", "snippet": "A new study reports heart benefits for patient with chronic kidney disease who took Vytorin to lower their cholesterol.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://prescriptions.blogs.nytimes.com/2010/11/20/lowering-bad-cholesterol-reduced-heart-problems-in-kidney-patients-study-shows/", "multimedia": [], "subsection_name": null, "keywords": [{"value": "Kidneys", "name": "subject", "rank": "4"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3"}, {"value": "Cholesterol", "name": "subject", "rank": "2"}, {"value": "Vytorin (Drug)", "name": "subject", "rank": "5"}, {"value": "News", "name": "type_of_material", "rank": "1"}, {"value": "Merck & Company Inc", "name": "organizations", "rank": "6"}, {"value": "Baigent, Colin", "name": "persons", "rank": "7"}, {"value": "Merck & Company Inc|MRK|NYSE", "name": "unknown", "rank": "8"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Natasha", "lastname": "SINGER"}], "original": "By NATASHA SINGER"}, "document_type": "blogpost", "pub_date": "2010-11-20T14:14:53Z", "section_name": "Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "The painkilling drug propoxyphene, sold under the Darvon and Darvocet brands and used by about 10 million Americans last year, will be removed from the market because of serious heart risks, the Food and Drug Administration said on Friday. The announcement ended a 32-year dispute over the safety of the 53-year-old drug. The F.D.A. recommended doctors switch patients to other painkillers, notably Extra Strength Tylenol or acetaminophen.", "headline": {"main": "Painkiller To Be Pulled Off Market"}, "abstract": "Food and Drug Administration says painkiller drug propoxyphene will be removed from market because of serious heart risks; drug is sold under Darvon and Darvocet brands and was used by 10 million Americans in 2009; photo (M)", "print_page": "1", "word_count": 764, "_id": "4fd2aa768eb7c8105d896b13", "snippet": "The painkilling drug propoxyphene, sold under the Darvon and Darvocet brands and used by about 10 million Americans last year, will be removed from the market because of serious heart risks, the Food and Drug Administration said on Friday.     The...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9801E5D6143DF933A15752C1A9669D8B63", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "PROPOXYPHENE (DRUG)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PAIN"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Duff", "rank": 1, "lastname": "WILSON"}], "original": "By DUFF WILSON"}, "document_type": "article", "pub_date": "2010-11-20T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "Blog", "blog": [], "news_desk": null, "lead_paragraph": "The painkilling drug propoxyphene, sold under the Darvon and Darvocet brands and used by about 10 million Americans last year, will be removed from the market because of serious heart risks, the Food and Drug Administration said on Friday.", "headline": {"main": "Darvon Pulled From Market by F.D.A.", "kicker": "Prescriptions"}, "abstract": "The pain killer and related drugs can cause fatal heart rhythms.", "print_page": null, "word_count": 732, "_id": "4fd39d128eb7c8105d8ddf2f", "snippet": "The pain killer and related drugs can cause fatal heart rhythms.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://prescriptions.blogs.nytimes.com/2010/11/19/darvon-pulled-from-market-by-f-d-a/", "multimedia": [], "subsection_name": null, "keywords": [{"value": "News", "name": "type_of_material", "rank": "1"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Duff", "lastname": "WILSON"}], "original": "By DUFF WILSON"}, "document_type": "blogpost", "pub_date": "2010-11-19T14:03:09Z", "section_name": "Health"}, {"type_of_material": "Blog", "blog": [], "news_desk": null, "lead_paragraph": "Look out Drs. - and New Yorker staff writers - Jerome Groopman and Atul Gawande.", "headline": {"main": "What We're Reading: Dr. Author", "kicker": "Prescriptions"}, "abstract": "A bioethicist examines ghostwriting while a cancer expert debunks lung-cancer screening.", "print_page": null, "word_count": 494, "_id": "4fd39d338eb7c8105d8de32d", "snippet": "A bioethicist examines ghostwriting while a cancer expert debunks lung-cancer screening.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://prescriptions.blogs.nytimes.com/2010/11/18/what-were-reading-dr-author/", "multimedia": [], "subsection_name": null, "keywords": [{"value": "News", "name": "type_of_material", "rank": "1"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Natasha", "lastname": "SINGER"}], "original": "By NATASHA SINGER"}, "document_type": "blogpost", "pub_date": "2010-11-18T13:56:37Z", "section_name": "Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "Patients taking the drug anacetrapib had a 39.8 percent reduction in bad cholesterol and a 138.1 percent increase in good cholesterol.", "headline": {"seo": "Merck Drug to Raise Good Cholesterol and Lower Bad Shows Promise", "main": "Merck Drug for Cutting Cholesterol Is Promising", "print_headline": "Merck Drug For Cutting Cholesterol Is Promising"}, "abstract": null, "print_page": "4", "word_count": "682", "_id": "5420bc997988104c4a501813", "snippet": "Patients taking the drug anacetrapib had a 39.8 percent reduction in bad cholesterol and a 138.1 percent increase in good cholesterol.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2010/11/18/health/research/18merck.html", "multimedia": [], "subsection_name": "Research", "keywords": [{"rank": "1", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Cholesterol", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Merck & Company Inc", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Research", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Medicine and Health", "name": "subject"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "firstname": "Natasha", "rank": 1, "lastname": "SINGER"}], "original": "By NATASHA SINGER"}, "document_type": "article", "pub_date": "2010-11-18T00:00:00Z", "section_name": "Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Science", "lead_paragraph": "A large study shows that nesiritide, which a smaller study had suggested had great promise, does not seem to be particularly effective.", "headline": {"seo": "Heart Failure Study Debunks Findings on Nesiritide", "main": "Good News and Bad From a Heart Study", "print_headline": "Good News and Bad From a Heart Study"}, "abstract": null, "print_page": "6", "word_count": "1026", "_id": "5420a8e47988104c4a501667", "snippet": "A large study shows that nesiritide, which a smaller study had suggested had great promise, does not seem to be particularly effective.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2010/11/16/health/16heart.html", "multimedia": [], "subsection_name": null, "keywords": [{"rank": "1", "is_major": "N", "value": "Zetia (Drug)", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Cholesterol", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Vytorin (Drug)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Medicine and Health", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "firstname": "Gina", "rank": 1, "lastname": "KOLATA"}, {"organization": "", "role": "reported", "firstname": "Natasha", "rank": 2, "lastname": "SINGER"}], "original": "By GINA KOLATA and NATASHA SINGER"}, "document_type": "article", "pub_date": "2010-11-16T00:00:00Z", "section_name": "Health"}], "meta": {"hits": 7, "offset": 0, "time": 234}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}